Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Up 8.3% in November

Iterum Therapeutics plc (NASDAQ:ITRM) was the recipient of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 2,740,000 shares, an increase of 8.3% from the October 31st total of 2,530,000 shares. Currently, 10.3% of the shares of the stock are sold short. Based on an average trading volume of 2,480,000 shares, the short-interest ratio is presently 1.1 days.

Institutional Trading of Iterum Therapeutics

An institutional investor recently bought a new position in Iterum Therapeutics stock. XTX Topco Ltd bought a new stake in shares of Iterum Therapeutics plc (NASDAQ:ITRM) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 33,040 shares of the company’s stock, valued at approximately $36,000. XTX Topco Ltd owned 0.15% of Iterum Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 9.21% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Iterum Therapeutics in a report on Tuesday, September 10th.

Iterum Therapeutics Stock Performance

Iterum Therapeutics stock opened at $2.24 on Wednesday. Iterum Therapeutics has a 1 year low of $0.81 and a 1 year high of $2.52. The firm’s 50 day moving average price is $1.33 and its two-hundred day moving average price is $1.27.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.